CDEK
← All drugs Report issue

luteinizing hormone

Biologicalapproved

Approved

Aug 22, 1975

Clinical trial activity

4 trials · 8 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Oct 4, 2023 (NCT06059118)

Timeline

1970s

  1. Aug 22, 1975

    Merck Serono — Earliest FDA Approval

  2. Aug 22, 1975

    Merck Serono — NDA Secondary Org

  3. Aug 22, 1975

    Merck Serono — NDA Organization

2020s

  1. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedAug 22, 1975

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07142551Phase 2Dec 30, 2025Bayer, Johns Hopkins University
NCT06922318Phase 2Aug 19, 2025Johns Hopkins University, National Cancer Institute (NCI), Zenith Epigenetics
NCT07128394N/AFeb 1, 2024Nanjing University
NCT06059118Phase 2Oct 4, 2023Department of Defense, Johns Hopkins University, Panbela Therapeutics, Prostate Cancer Foundation
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Johns Hopkins UniversityAcademic/Hospital3312023
BayerFor profit1012025
Department of DefenseGovernment1012023
Nanjing UniversityAcademic/Hospital1112024
National Cancer Institute (NCI)Government1012025
Panbela TherapeuticsFor profit1012023
Prostate Cancer FoundationAcademic/Hospital1012023
Zenith EpigeneticsFor profit1012025
8 organizations
Page 1 / 1

Marketing (2)

OrganizationOrg typeRelationshipDate
Merck SeronoFor profitNDA2Aug 22, 1975
Merck SeronoFor profitNDAAug 22, 1975